Literature DB >> 22307842

Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.

Sean van Diepen1, Matthew T Roe, Renato D Lopes, Amanda Stebbins, Stefan James, L Kristin Newby, David J Moliterno, Franz-Josef Neumann, Justin A Ezekowitz, Kenneth W Mahaffey, Judith S Hochman, Christian W Hamm, Paul W Armstrong, Pierre Theroux, Christopher B Granger.   

Abstract

Coronary plaque rupture is associated with a systemic inflammatory response. The relationship between baseline N-terminal pro B-type natriuretic peptide (NT-proBNP), a prognostic marker in patients with acute coronary syndromes, and systemic inflammatory mediators in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) is not well described. Of 5,745 STEMI patients treated with primary PCI in the APEX-AMI trial, we evaluated the relationship between baseline NT-proBNP levels and baseline levels of inflammatory markers and markers of myonecrosis in a subset of 772 who were enrolled in a biomarker substudy. Spearman correlations (r (s)) were calculated between baseline NT-proBNP levels and a panel of ten systemic inflammatory biomarkers. Interleukin (IL)-6, a pro-inflammatory cytokine, was significantly positively correlated with NT-proBNP (r (s) = 0.317, P < 0.001). In a sensitivity analysis excluding all heart failure patients, the correlation between baseline IL-6 and NT-proBNP remained significant (n = 651, r (s) = 0.296, P < 0.001). A positive association was also observed with high sensitivity C-reactive protein (r (s) = 0.377, P < 0.001) and there was a weak negative correlation with the anti-inflammatory cytokine IL-10 (r (s) = -0.109, P = 0.003). No other significant correlations were observed among the other testes inflammatory cytokines and chemokines. In STEMI patients undergoing primary PCI, the pro-inflammatory cytokine IL-6 was modestly correlated with baseline NT-proBNP levels. This relationship remained significant in patients without heart failure. This finding is consistent with pre-clinical and clinical research suggesting that systemic inflammation may influence NT-proBNP expression independently of myocardial stretch.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22307842     DOI: 10.1007/s11239-012-0691-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  40 in total

1.  B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction.

Authors:  Micha Maeder; Peter Ammann; Wolfgang Kiowski; Hans Rickli
Journal:  Eur J Heart Fail       Date:  2005-10-03       Impact factor: 15.534

2.  Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

Authors:  Paul W Armstrong; Christopher B Granger; Peter X Adams; Christian Hamm; David Holmes; William W O'Neill; Thomas G Todaro; Alec Vahanian; Frans Van de Werf
Journal:  JAMA       Date:  2007-01-03       Impact factor: 56.272

3.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.

Authors:  T Tsutamoto; T Hisanaga; A Wada; K Maeda; M Ohnishi; D Fukai; N Mabuchi; M Sawaki; M Kinoshita
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

4.  Endothelin-1 and cardiotrophin-1 induce brain natriuretic peptide gene expression by distinct transcriptional mechanisms.

Authors:  K Kuwahara; Y Saito; Y Ogawa; N Tamura; M Ishikawa; M Harada; E Ogawa; Y Miyamoto; I Hamanaka; S Kamitani; N Kajiyama; N Takahashi; O Nakagawa; I Masuda; K Nakao
Journal:  J Cardiovasc Pharmacol       Date:  1998       Impact factor: 3.105

5.  Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Stefanie Dimmeler; Christian W Hamm; Stephan Fichtlscherer; Eric Boersma; Maarten L Simoons; Andreas M Zeiher
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

6.  Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats.

Authors:  Alexander Deten; Hans Christian Volz; Wilfried Briest; Heinz-Gerd Zimmer
Journal:  Cardiovasc Res       Date:  2002-08-01       Impact factor: 10.787

7.  B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.

Authors:  A Mark Richards; M Gary Nicholls; Eric A Espiner; John G Lainchbury; Richard W Troughton; John Elliott; Christopher Frampton; John Turner; Ian G Crozier; Timothy G Yandle
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

8.  B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.

Authors:  Jessica L Mega; David A Morrow; James A De Lemos; Marc S Sabatine; Sabina A Murphy; Nader Rifai; C Michael Gibson; Elliott M Antman; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2004-07-21       Impact factor: 24.094

9.  Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages.

Authors:  V Chiurchiù; V Izzi; F D'Aquilio; F Carotenuto; P Di Nardo; P M Baldini
Journal:  Regul Pept       Date:  2008-03-10

10.  ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.

Authors:  Christopher E Buller; Yuling Fu; Kenneth W Mahaffey; Thomas G Todaro; Peter Adams; Cynthia M Westerhout; Harvey D White; Arnoud W J van 't Hof; Frans J Van de Werf; Galen S Wagner; Christopher B Granger; Paul W Armstrong
Journal:  Circulation       Date:  2008-09-08       Impact factor: 29.690

View more
  8 in total

1.  Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction.

Authors:  Sean van Diepen; Wendimagegn G Alemayehu; Yinggan Zheng; Pierre Theroux; L Kristin Newby; Kenneth W Mahaffey; Christopher B Granger; Paul W Armstrong
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

2.  Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.

Authors:  Sahera Dirajlal-Fargo; Bruce Kinley; Ying Jiang; Chris T Longenecker; Corrilynn O Hileman; Sara Debanne; Grace A McComsey
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

3.  Cross-sex hormonal replacement: is this really effective? an experimental clue.

Authors:  Natalia Pavón; Israel Pérez-Torres; Alberto Aranda; Francisco-Javier Roldán; Cristina Paredes; Edmundo Chávez
Journal:  Endocrine       Date:  2013-02-26       Impact factor: 3.633

4.  IL-6 signalling in patients with acute ST-elevation myocardial infarction.

Authors:  Vibeke N Ritschel; Ingebjørg Seljeflot; Harald Arnesen; Sigrun Halvorsen; Thomas Weiss; Jan Eritsland; Geir Ø Andersen
Journal:  Results Immunol       Date:  2013-12-14

5.  The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Otto A Sanchez; Daniel A Duprez; Hossein Bahrami; Lori B Daniels; Aaron R Folsom; Joao A Lima; Alan Maisel; Carmen A Peralta; David R Jacobs
Journal:  Metabolism       Date:  2013-11-27       Impact factor: 8.694

6.  Complement C3c as a biomarker in heart failure.

Authors:  A Frey; G Ertl; C E Angermann; U Hofmann; S Störk; S Frantz
Journal:  Mediators Inflamm       Date:  2013-12-30       Impact factor: 4.711

7.  Salidroside decreases atherosclerotic plaque formation in low-density lipoprotein receptor-deficient mice.

Authors:  Bu-Chun Zhang; Wei-Ming Li; Rong Guo; Ya-Wei Xu
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-10       Impact factor: 2.629

Review 8.  Emerging families of biomarkers for coronary artery disease: inflammatory mediators.

Authors:  Josef Yayan
Journal:  Vasc Health Risk Manag       Date:  2013-07-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.